{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T09:36:32Z","timestamp":1764322592619,"version":"3.46.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orthop\u00e4die"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00132-025-04725-5","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T09:40:14Z","timestamp":1757929214000},"page":"958-963","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antiresorptive Therapie der Osteoporose","Antiresorptive therapies in osteoporosis"],"prefix":"10.1007","volume":"54","author":[{"given":"Konstantin","family":"Horas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Kurth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"4725_CR1","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00132-007-1106-3","volume":"36","author":"AA Kurth","year":"2007","unstructured":"Kurth\u00a0AA, Pfeilschifter\u00a0J (2007) Diagnosis and treatment of postmenopausal osteoporosis and osteoporosis in men. German Guidelines Update 2006. Orthopade 36:683\u2013690. https:\/\/doi.org\/10.1007\/s00132-007-1106-3 (quiz 691)","journal-title":"Orthopade"},{"key":"4725_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11657-024-01380-9","volume":"19","author":"P Hadji","year":"2024","unstructured":"Hadji\u00a0P, Esterberg\u00a0E, Oberm\u00fcller\u00a0D, Bartsch\u00a0R (2024) Bone evaluation study-2: update on the epidemiology of osteoporosis in Germany. Arch Osteoporos 19:26. https:\/\/doi.org\/10.1007\/s11657-024-01380-9","journal-title":"Arch Osteoporos"},{"key":"4725_CR3","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.2174\/1871530320666200604160614","volume":"20","author":"NV Mohamad","year":"2020","unstructured":"Mohamad\u00a0NV, Ima-Nirwana\u00a0S, Chin\u00a0KY (2020) Are oxidative stress and inflammation mediators of bone loss due to estrogen deficiency? A\u00a0review of current evidence. Endocr Metab Immune Disord Drug Targets 20:1478\u20131487. https:\/\/doi.org\/10.2174\/1871530320666200604160614","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"4725_CR4","doi-asserted-by":"publisher","first-page":"115516","DOI":"10.1016\/j.bone.2020.115516","volume":"139","author":"B Langdahl","year":"2020","unstructured":"Langdahl\u00a0B (2020) Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: combined and sequential approaches. Bone 139:115516. https:\/\/doi.org\/10.1016\/j.bone.2020.115516","journal-title":"Bone"},{"key":"4725_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s00113-019-0677-x","volume":"122","author":"F Thomasius","year":"2019","unstructured":"Thomasius\u00a0F, Hadji\u00a0P (2019) Einfluss einer Hormon- oder Hormonersatztherapie auf die Knochenheilung. Unfallchirurg 122:512\u2013517. https:\/\/doi.org\/10.1007\/s00113-019-0677-x","journal-title":"Unfallchirurg"},{"key":"4725_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12081830","author":"E Umur","year":"2024","unstructured":"Umur\u00a0E, Bulut\u00a0SB, Yi\u011fit\u00a0P, Bayrak\u00a0E, Arkan\u00a0Y, Arslan\u00a0F, Baysoy\u00a0E, Kaleli-Can\u00a0G, Ayan\u00a0B (2024) Exploring the role of hormones and cytokines in osteoporosis development. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines12081830","journal-title":"Biomedicines"},{"key":"4725_CR7","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3389\/fphar.2017.00803","volume":"8","author":"V Pavone","year":"2017","unstructured":"Pavone\u00a0V, Testa\u00a0G, Giardina\u00a0SMC, Vescio\u00a0A, Restivo\u00a0DA, Sessa\u00a0G (2017) Pharmacological therapy of osteoporosis: a\u00a0systematic current review of literature. Front Pharmacol 8:803. https:\/\/doi.org\/10.3389\/fphar.2017.00803","journal-title":"Front Pharmacol"},{"key":"4725_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00129-019-04537-7","volume":"53","author":"F Thomasius","year":"2020","unstructured":"Thomasius\u00a0F, Hadji\u00a0P (2020) Pr\u00e4vention und Therapie der postmenopausalen Osteoporose. Gyn\u00e4kologe 53:19\u201324. https:\/\/doi.org\/10.1007\/s00129-019-04537-7","journal-title":"Gyn\u00e4kologe"},{"key":"4725_CR9","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","volume":"290","author":"JA Cauley","year":"2003","unstructured":"Cauley\u00a0JA, Robbins\u00a0J, Chen\u00a0Z, Cummings\u00a0SR, Jackson\u00a0RD, LaCroix\u00a0AZ, LeBoff\u00a0M, Lewis\u00a0CE, McGowan\u00a0J, Neuner\u00a0J et\u00a0al (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the women\u2019s health initiative randomized trial. JAMA 290:1729\u20131738. https:\/\/doi.org\/10.1001\/jama.290.13.1729","journal-title":"JAMA"},{"key":"4725_CR10","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","volume":"291","author":"GL Anderson","year":"2004","unstructured":"Anderson\u00a0GL, Limacher\u00a0M, Assaf\u00a0AR, Bassford\u00a0T, Beresford\u00a0SA, Black\u00a0H, Bonds\u00a0D, Brunner\u00a0R, Brzyski\u00a0R, Caan\u00a0B et\u00a0al (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women\u2019s health initiative randomized controlled trial. JAMA 291:1701\u20131712. https:\/\/doi.org\/10.1001\/jama.291.14.1701","journal-title":"JAMA"},{"key":"4725_CR11","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","volume":"33","author":"MS LeBoff","year":"2022","unstructured":"LeBoff\u00a0MS, Greenspan\u00a0SL, Insogna\u00a0KL, Lewiecki\u00a0EM, Saag\u00a0KG, Singer\u00a0AJ, Siris\u00a0ES (2022) The clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 33:2049\u20132102. https:\/\/doi.org\/10.1007\/s00198-021-05900-y","journal-title":"Osteoporos Int"},{"key":"4725_CR12","first-page":"92","volume":"43","author":"KN Tu","year":"2018","unstructured":"Tu\u00a0KN, Lie\u00a0JD, Wan\u00a0CKV, Cameron\u00a0M, Austel\u00a0AG, Nguyen\u00a0JK, Van\u00a0K, Hyun\u00a0D (2018) Osteoporosis: a\u00a0review of treatment options. P\u00a0T 43:92\u2013104","journal-title":"P T"},{"key":"4725_CR13","unstructured":"S3-Leitlinie Prophylaxe, Diagnostik und Therapie der Osteoporose bei postmenopausalen Frauen und bei M\u00e4nnern ab dem 50.\u00a0Lebensjahr"},{"key":"4725_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12081635","author":"NR Elahmer","year":"2024","unstructured":"Elahmer\u00a0NR, Wong\u00a0SK, Mohamed\u00a0N, Alias\u00a0E, Chin\u00a0KY, Muhammad\u00a0N (2024) Mechanistic insights and therapeutic strategies in osteoporosis: a\u00a0comprehensive review. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines12081635","journal-title":"Biomedicines"},{"key":"4725_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40199-017-0167-z","volume":"25","author":"O Tabatabaei-Malazy","year":"2017","unstructured":"Tabatabaei-Malazy\u00a0O, Salari\u00a0P, Khashayar\u00a0P, Larijani\u00a0B (2017) New horizons in treatment of osteoporosis. Daru 25:2. https:\/\/doi.org\/10.1186\/s40199-017-0167-z","journal-title":"Daru"},{"key":"4725_CR16","doi-asserted-by":"publisher","first-page":"e49079","DOI":"10.7759\/cureus.49079","volume":"15","author":"G Motlani","year":"2023","unstructured":"Motlani\u00a0G, Motlani\u00a0V, Acharya\u00a0N, Dave\u00a0A, Pamnani\u00a0S, Somyani\u00a0D, Agrawal\u00a0S (2023) Novel advances in the role of selective estrogen receptor modulators in hormonal replacement therapy: a\u00a0paradigm shift. Cureus 15:e49079. https:\/\/doi.org\/10.7759\/cureus.49079","journal-title":"Cureus"},{"key":"4725_CR17","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.bone.2009.02.014","volume":"44","author":"JA Kanis","year":"2009","unstructured":"Kanis\u00a0JA, Johansson\u00a0H, Oden\u00a0A, McCloskey\u00a0EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 44:1049\u20131054. https:\/\/doi.org\/10.1016\/j.bone.2009.02.014","journal-title":"Bone"},{"key":"4725_CR18","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.fertnstert.2009.02.093","volume":"92","author":"R Lindsay","year":"2009","unstructured":"Lindsay\u00a0R, Gallagher\u00a0JC, Kagan\u00a0R, Pickar\u00a0JH, Constantine\u00a0G (2009) Efficacy of tissue-selective estrogen complex of bazedoxifene\/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 92:1045\u20131052. https:\/\/doi.org\/10.1016\/j.fertnstert.2009.02.093","journal-title":"Fertil Steril"},{"key":"4725_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/13685538.2018.1448058","volume":"22","author":"SK Wong","year":"2019","unstructured":"Wong\u00a0SK, Mohamad\u00a0NV, Jayusman\u00a0PA, Shuid\u00a0AN, Ima-Nirwana\u00a0S, Chin\u00a0KY (2019) The use of selective estrogen receptor modulators on bone health in men. Aging Male 22:89\u2013101. https:\/\/doi.org\/10.1080\/13685538.2018.1448058","journal-title":"Aging Male"},{"key":"4725_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3109\/13685538.2015.1004049","volume":"18","author":"B Lunenfeld","year":"2015","unstructured":"Lunenfeld\u00a0B, Mskhalaya\u00a0G, Zitzmann\u00a0M, Arver\u00a0S, Kalinchenko\u00a0S, Tishova\u00a0Y, Morgentaler\u00a0A (2015) Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male 18:5\u201315. https:\/\/doi.org\/10.3109\/13685538.2015.1004049","journal-title":"Aging Male"},{"key":"4725_CR21","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrendo.2009.112","volume":"5","author":"L Vandenput","year":"2009","unstructured":"Vandenput\u00a0L, Ohlsson\u00a0C (2009) Estrogens as regulators of bone health in men. Nat Rev Endocrinol 5:437\u2013443. https:\/\/doi.org\/10.1038\/nrendo.2009.112","journal-title":"Nat Rev Endocrinol"},{"key":"4725_CR22","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/1471-2474-14-366","volume":"14","author":"LT Ho-Pham","year":"2013","unstructured":"Ho-Pham\u00a0LT, Nguyen\u00a0ND, Nguyen\u00a0TV (2013) Quantification of the relative contribution of estrogen to bone mineral density in men and women. BMC Musculoskelet Disord 14:366. https:\/\/doi.org\/10.1186\/1471-2474-14-366","journal-title":"BMC Musculoskelet Disord"},{"key":"4725_CR23","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s00198-010-1276-4","volume":"22","author":"P Vestergaard","year":"2011","unstructured":"Vestergaard\u00a0P, Schwartz\u00a0K, Pinholt\u00a0EM, Rejnmark\u00a0L, Mosekilde\u00a0L (2011) Stroke in relation to use of raloxifene and other drugs against osteoporosis. Osteoporos Int 22:1037\u20131045. https:\/\/doi.org\/10.1007\/s00198-010-1276-4","journal-title":"Osteoporos Int"},{"key":"4725_CR24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1001\/jama.2020.2923","volume":"325","author":"KE Ensrud","year":"2021","unstructured":"Ensrud\u00a0KE (2021) Bisphosphonates for postmenopausal osteoporosis. JAMA 325:96. https:\/\/doi.org\/10.1001\/jama.2020.2923","journal-title":"JAMA"},{"key":"4725_CR25","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s00132-006-1035-6","volume":"36","author":"S Reinsdorf","year":"2007","unstructured":"Reinsdorf\u00a0S, Habermann\u00a0B, Hochmuth\u00a0K, Kurth\u00a0AA (2007) Bisphosphonates in osteoporosis therapy. Standards and perspectives. Orthopade 36:110\u2013117. https:\/\/doi.org\/10.1007\/s00132-006-1035-6","journal-title":"Orthopade"},{"key":"4725_CR26","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s00223-025-01390-w","volume":"116","author":"H Hadad","year":"2025","unstructured":"Hadad\u00a0H, de Jesus\u00a0LK, da Silva\u00a0MP, Oliveira\u00a0M, Guastaldi\u00a0FPS, Nilsson\u00a0O, Okamoto\u00a0R, Souza\u00a0F (2025) A\u00a0systematic review of the effects of bisphosphonates on osteoblasts in vitro. Calcif Tissue Int 116:86. https:\/\/doi.org\/10.1007\/s00223-025-01390-w","journal-title":"Calcif Tissue Int"},{"key":"4725_CR27","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/bcp.13867","volume":"85","author":"S Cremers","year":"2019","unstructured":"Cremers\u00a0S, Drake\u00a0MT, Ebetino\u00a0FH, Bilezikian\u00a0JP, Russell\u00a0RGG (2019) Pharmacology of bisphosphonates. Br J Clin Pharmacol 85:1052\u20131062. https:\/\/doi.org\/10.1111\/bcp.13867","journal-title":"Br J Clin Pharmacol"},{"key":"4725_CR28","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1210\/jc.2009-1947","volume":"95","author":"NB Watts","year":"2010","unstructured":"Watts\u00a0NB, Diab\u00a0DL (2010) Long-term use of bisphosphonates in osteoporosis. J\u00a0Clin Endocrinol Metab 95:1555\u20131565. https:\/\/doi.org\/10.1210\/jc.2009-1947","journal-title":"J Clin Endocrinol Metab"},{"key":"4725_CR29","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.2174\/0929867327666200330142432","volume":"28","author":"H Li","year":"2021","unstructured":"Li\u00a0H, Xiao\u00a0Z, Quarles\u00a0LD, Li\u00a0W (2021) Osteoporosis: mechanism, molecular target and current status on drug development. Curr Med Chem 28:1489\u20131507. https:\/\/doi.org\/10.2174\/0929867327666200330142432","journal-title":"Curr Med Chem"},{"key":"4725_CR30","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/s0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black\u00a0DM, Cummings\u00a0SR, Karpf\u00a0DB, Cauley\u00a0JA, Thompson\u00a0DE, Nevitt\u00a0MC, Bauer\u00a0DC, Genant\u00a0HK, Haskell\u00a0WL, Marcus\u00a0R et\u00a0al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535\u20131541. https:\/\/doi.org\/10.1016\/s0140-6736(96)07088-2","journal-title":"Lancet"},{"key":"4725_CR31","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings\u00a0SR, Black\u00a0DM, Thompson\u00a0DE, Applegate\u00a0WB, Barrett-Connor\u00a0E, Musliner\u00a0TA, Palermo\u00a0L, Prineas\u00a0R, Rubin\u00a0SM, Scott\u00a0JC et\u00a0al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 280:2077\u20132082. https:\/\/doi.org\/10.1001\/jama.280.24.2077","journal-title":"JAMA"},{"key":"4725_CR32","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1359\/jbmr.040325","volume":"19","author":"CH Chesnut 3rd","year":"2004","unstructured":"Chesnut\u00a0CH 3rd, Skag\u00a0A, Christiansen\u00a0C, Recker\u00a0R, Stakkestad\u00a0JA, Hoiseth\u00a0A, Felsenberg\u00a0D, Huss\u00a0H, Gilbride\u00a0J, Schimmer\u00a0RC et\u00a0al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J\u00a0Bone Miner Res 19:1241\u20131249. https:\/\/doi.org\/10.1359\/jbmr.040325","journal-title":"J Bone Miner Res"},{"key":"4725_CR33","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2019-00192","volume":"104","author":"P Barrionuevo","year":"2019","unstructured":"Barrionuevo\u00a0P, Kapoor\u00a0E, Asi\u00a0N, Alahdab\u00a0F, Mohammed\u00a0K, Benkhadra\u00a0K, Almasri\u00a0J, Farah\u00a0W, Sarigianni\u00a0M, Muthusamy\u00a0K et\u00a0al (2019) Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a\u00a0network meta-analysis. J\u00a0Clin Endocrinol Metab 104:1623\u20131630. https:\/\/doi.org\/10.1210\/jc.2019-00192","journal-title":"J Clin Endocrinol Metab"},{"key":"4725_CR34","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black\u00a0DM, Delmas\u00a0PD, Eastell\u00a0R, Reid\u00a0IR, Boonen\u00a0S, Cauley\u00a0JA, Cosman\u00a0F, Lakatos\u00a0P, Leung\u00a0PC, Man\u00a0Z et\u00a0al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N\u00a0Engl J Med 356:1809\u20131822. https:\/\/doi.org\/10.1056\/NEJMoa067312","journal-title":"N Engl J Med"},{"key":"4725_CR35","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2407031","volume":"392","author":"MJ Bolland","year":"2025","unstructured":"Bolland\u00a0MJ, Nisa\u00a0Z, Mellar\u00a0A, Gasteiger\u00a0C, Pinel\u00a0V, Mihov\u00a0B, Bastin\u00a0S, Grey\u00a0A, Reid\u00a0IR, Gamble\u00a0G et\u00a0al (2025) Fracture prevention with infrequent zoledronate in women 50 to 60 years of age. N\u00a0Engl J Med 392:239\u2013248. https:\/\/doi.org\/10.1056\/NEJMoa2407031","journal-title":"N Engl J Med"},{"key":"4725_CR36","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1185\/030079905x61875","volume":"21","author":"JA Cramer","year":"2005","unstructured":"Cramer\u00a0JA, Amonkar\u00a0MM, Hebborn\u00a0A, Altman\u00a0R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453\u20131460. https:\/\/doi.org\/10.1185\/030079905x61875","journal-title":"Curr Med Res Opin"},{"key":"4725_CR37","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00198-024-07262-7","volume":"36","author":"R Persson","year":"2025","unstructured":"Persson\u00a0R, Hagberg\u00a0KW, Pranschke\u00a0E, Vasilakis-Scaramozza\u00a0C, Jick\u00a0S (2025) Treatment for osteoporosis and risk of osteonecrosis of the jaw among female patients in the United Kingdom clinical practice research datalink. Osteoporos Int 36:47\u201360. https:\/\/doi.org\/10.1007\/s00198-024-07262-7","journal-title":"Osteoporos Int"},{"key":"4725_CR38","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1002\/jbmr.253","volume":"25","author":"E Shane","year":"2010","unstructured":"Shane\u00a0E, Burr\u00a0D, Ebeling\u00a0PR, Abrahamsen\u00a0B, Adler\u00a0RA, Brown\u00a0TD, Cheung\u00a0AM, Cosman\u00a0F, Curtis\u00a0JR, Dell\u00a0R et\u00a0al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a\u00a0task force of the American society for bone and mineral research. J\u00a0Bone Miner Res 25:2267\u20132294. https:\/\/doi.org\/10.1002\/jbmr.253","journal-title":"J Bone Miner Res"},{"key":"4725_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"Shane\u00a0E, Burr\u00a0D, Abrahamsen\u00a0B, Adler\u00a0RA, Brown\u00a0TD, Cheung\u00a0AM, Cosman\u00a0F, Curtis\u00a0JR, Dell\u00a0R, Dempster\u00a0DW et\u00a0al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a\u00a0task force of the American society for bone and mineral research. J\u00a0Bone Miner Res 29:1\u201323. https:\/\/doi.org\/10.1002\/jbmr.1998","journal-title":"J Bone Miner Res"},{"key":"4725_CR40","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11657-024-01452-w","volume":"19","author":"CH Chen","year":"2024","unstructured":"Chen\u00a0CH, Yeap\u00a0EK, Hsu\u00a0CH, Lu\u00a0YM, Cheng\u00a0TL, Lee\u00a0TC, Ho\u00a0CJ, Li\u00a0JY, Shen\u00a0HY, Huang\u00a0HT et\u00a0al (2024) Novel combined pharmacological strategy to alleviate acute phase response following zoledronic acid treatment. Arch Osteoporos 19:97. https:\/\/doi.org\/10.1007\/s11657-024-01452-w","journal-title":"Arch Osteoporos"},{"key":"4725_CR41","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41586-018-0482-7","volume":"561","author":"Y Ikebuchi","year":"2018","unstructured":"Ikebuchi\u00a0Y, Aoki\u00a0S, Honma\u00a0M, Hayashi\u00a0M, Sugamori\u00a0Y, Khan\u00a0M, Kariya\u00a0Y, Kato\u00a0G, Tabata\u00a0Y, Penninger\u00a0JM et\u00a0al (2018) Coupling of bone resorption and formation by RANKL reverse signalling. Nature 561:195\u2013200. https:\/\/doi.org\/10.1038\/s41586-018-0482-7","journal-title":"Nature"},{"key":"4725_CR42","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.tem.2017.06.003","volume":"28","author":"S Portal-N\u00fa\u00f1ez","year":"2017","unstructured":"Portal-N\u00fa\u00f1ez\u00a0S, Mediero\u00a0A, Esbrit\u00a0P, S\u00e1nchez-Pernaute\u00a0O, Largo\u00a0R, Herrero-Beaumont\u00a0G (2017) Unexpected bone formation produced by RANKL blockade. Trends Endocrinol Metab 28:695\u2013704. https:\/\/doi.org\/10.1016\/j.tem.2017.06.003","journal-title":"Trends Endocrinol Metab"},{"key":"4725_CR43","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41584-023-00935-3","volume":"19","author":"S Ferrari","year":"2023","unstructured":"Ferrari\u00a0S, Langdahl\u00a0B (2023) Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone. Nat Rev Rheumatol 19:307\u2013317. https:\/\/doi.org\/10.1038\/s41584-023-00935-3","journal-title":"Nat Rev Rheumatol"},{"key":"4725_CR44","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/s2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone\u00a0HG, Wagman\u00a0RB, Brandi\u00a0ML, Brown\u00a0JP, Chapurlat\u00a0R, Cummings\u00a0SR, Czerwi\u0144ski\u00a0E, Fahrleitner-Pammer\u00a0A, Kendler\u00a0DL, Lippuner\u00a0K et\u00a0al (2017) 10\u00a0years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase\u00a03 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513\u2013523. https:\/\/doi.org\/10.1016\/s2213-8587(17)30138-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4725_CR45","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings\u00a0SR, Martin\u00a0JS, McClung\u00a0MR, Siris\u00a0ES, Eastell\u00a0R, Reid\u00a0IR, Delmas\u00a0P, Zoog\u00a0HB, Austin\u00a0M, Wang\u00a0A et\u00a0al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N\u00a0Engl J Med 361:756\u2013765. https:\/\/doi.org\/10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"key":"4725_CR46","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","volume":"39","author":"DL Kendler","year":"2022","unstructured":"Kendler\u00a0DL, Cosman\u00a0F, Stad\u00a0RK, Ferrari\u00a0S (2022) Denosumab in the treatment of osteoporosis: 10 years later: a\u00a0narrative review. Adv Ther 39:58\u201374. https:\/\/doi.org\/10.1007\/s12325-021-01936-y","journal-title":"Adv Ther"},{"key":"4725_CR47","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi\u00a0E, Langdahl\u00a0B, Cohen-Solal\u00a0M, Aubry-Rozier\u00a0B, Eriksen\u00a0EF, Gua\u00f1abens\u00a0N, Obermayer-Pietsch\u00a0B, Ralston\u00a0SH, Eastell\u00a0R, Zillikens\u00a0MC (2017) Discontinuation of Denosumab therapy for osteoporosis: a\u00a0systematic review and position statement by ECTS. Bone 105:11\u201317. https:\/\/doi.org\/10.1016\/j.bone.2017.08.003","journal-title":"Bone"}],"container-title":["Die Orthop\u00e4die"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00132-025-04725-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00132-025-04725-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00132-025-04725-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T09:32:11Z","timestamp":1764322331000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00132-025-04725-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4725"],"URL":"https:\/\/doi.org\/10.1007\/s00132-025-04725-5","relation":{},"ISSN":["2731-7145","2731-7153"],"issn-type":[{"type":"print","value":"2731-7145"},{"type":"electronic","value":"2731-7153"}],"subject":[],"published":{"date-parts":[[2025,9,15]]},"assertion":[{"value":"29 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Kurth: Vortr\u00e4ge (Firma Amgen). K.\u00a0Horas gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}